AEON Biopharma Net Income Over Time
| AEON Stock | 1.00 0.05 5.26% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out AEON Biopharma Performance and AEON Biopharma Correlation. Will Biotechnology sector continue expanding? Could AEON diversify its offerings? Factors like these will boost the valuation of AEON Biopharma. If investors know AEON will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every AEON Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate AEON Biopharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating AEON Biopharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause AEON Biopharma's market price to deviate significantly from intrinsic value.
Understanding that AEON Biopharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AEON Biopharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, AEON Biopharma's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare AEON Biopharma and related stocks such as Cingulate, Cellectar Biosciences, and Bolt Biotherapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CING | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (7.2 M) | (20.7 M) | (17.9 M) | (23.5 M) | (15.5 M) | (14 M) | (14.7 M) |
| CLRB | (815.3 K) | (7.4 M) | (8.8 M) | (10.8 M) | (8.1 M) | (5.5 M) | (6.2 M) | (13.6 M) | (13.2 M) | (14.1 M) | (15.1 M) | (24 M) | (28.6 M) | (42.8 M) | (44.6 M) | (40.1 M) | (38.1 M) |
| BOLT | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (30.5 M) | (60.7 M) | (98.6 M) | (88.1 M) | (69.2 M) | (63.1 M) | (56.8 M) | (59.6 M) |
| MRKR | (1.1 M) | (2 M) | (5.9 M) | (5.5 M) | (30.9 M) | (34.1 M) | (2.5 M) | (11 M) | (148 M) | (21.4 M) | (28.7 M) | (41.9 M) | (29.9 M) | (8.2 M) | (10.7 M) | (9.7 M) | (10.1 M) |
| OSRH | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (23.8 K) | (3.3 K) | (35.4 K) | 403.8 K | (2.4 M) | (2.2 M) | (2.1 M) |
| CLNN | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (277.3 K) | (16.2 M) | (19.3 M) | (9.7 M) | (29.9 M) | (49.5 M) | (39.4 M) | (35.5 M) | (33.7 M) |
| ABP | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (12.4 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (17.2 M) | (11.7 M) | (7.2 M) | (6.5 M) | (6.8 M) |
| MBIO | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (12.7 M) | (31.3 M) | (30.7 M) | (48.2 M) | (60 M) | (66.4 M) | (77.5 M) | (51.6 M) | (15.8 M) | (14.2 M) | (14.9 M) |
| APM | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.5 M) | (14.8 M) | (18.7 M) | 7.1 M | (25 M) | (9.8 M) | (2.8 M) | (4.3 M) | (3.8 M) | (4 M) |
| LYRA | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (16.3 M) | (22.1 M) | (42.4 M) | (55.3 M) | (62.7 M) | (93.4 M) | (84.1 M) | (79.9 M) |
AEON Biopharma and related stocks such as Cingulate, Cellectar Biosciences, and Bolt Biotherapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in AEON Biopharma financial statement analysis. It represents the amount of money remaining after all of AEON Biopharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| AEON Biopharma | AEON |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 5 Park Plaza, |
| Exchange | NYSE MKT Exchange |
null 1.0
Check out AEON Biopharma Performance and AEON Biopharma Correlation. To learn how to invest in AEON Stock, please use our How to Invest in AEON Biopharma guide.You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
AEON Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.